Form 4: Blueprint Medicines Corp: Chief Scientific Officer Sells Shares to Cover Tax Obligations

Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, sold 2,286 shares of common stock on March 7, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 7, 2024, Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines Corp, sold 2,286 shares of common stock.
• The shares were sold at a price of $90.69 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Carter directly owns 48,331 shares of Blueprint Medicines Corp.
• A Limited Power of Attorney was executed on January 29, 2023, granting certain individuals the authority to act on Carter's behalf regarding SEC filings.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Executive stock sales are a common occurrence and can be for various reasons, including diversification, tax obligations, or personal financial planning. This transaction appears to be related to tax obligations, which is a routine event.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but given the reason for the sale (tax obligations), the impact is likely to be minimal.

Key Dates